Target Name: NDRG4
NCBI ID: G65009
Review Report on NDRG4 Target / Biomarker Content of Review Report on NDRG4 Target / Biomarker
NDRG4
Other Name(s): DKFZp686I1615 | SMAP8 | NDRG family member 4 | SMAP-8 | BDM1 | vascular smooth muscle cell-associated protein 8 | Smooth muscle-associated protein 8 | NDRG4_HUMAN | KIAA1180 | MGC19632 | FLJ42011 | Protein NDRG4 (isoform 2) | Brain development-related molecule 1 | Protein NDRG4 (isoform 1) | smooth muscle-associated protein 8 | NDRG4 variant 1 | FLJ30586 | NDRG4 variant 2 | Vascular smooth muscle cell-associated protein 8 | Protein NDRG4 | brain development-related molecule 1 | N-myc downstream-regulated gene 4 protein | N-myc downstream-regulated gene 4 protein (NDRG4)

Understanding The Potential Therapeutic Targets of NDRG4

NDRG4 (DKFZp686I1615) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the neuroendocrine receptor G protein-coupled receptor (NGRC) family, which is a large superfamily of G protein-coupled receptors that play a crucial role in cellular signaling.

NGRC receptors are involved in a wide range of physiological processes in the body, including sensory perception, neurotransmitter signaling, and hormone regulation. They are also potential drug targets, as many of them have been identified as targets for small molecules and other therapeutic compounds.

One of the unique features of NDRG4 is its expression pattern in the brain. NDRG4 is highly expressed in the cerebral cortical cortical layer and lamellar structure, where it is involved in the regulation of neuronal excitability and synaptic plasticity.

NDRG4 is also involved in the regulation of pancreatic function, including insulin secretion and glucagon secretion. It is a potential drug target for pancreatic cancer, as pancreatic cancer is often associated with insulin resistance and high blood sugar levels.

In addition to its involvement in neuroendocrine function, NDRG4 is also thought to be involved in the regulation of inflammation. Studies have shown that NDRG4 is involved in the regulation of immune cell function and that it is a potential therapeutic target for various inflammatory diseases.

Despite its potential as a drug target, NDRG4 is not yet a well-studied protein. There are currently few studies that have specifically investigated the effects of NDRG4, and more research is needed to fully understand its role in cellular signaling and its potential as a therapeutic target.

In conclusion, NDRG4 is a protein that is expressed in various tissues of the body and is involved in a wide range of physiological processes. Its expression pattern in the brain and its potential involvement in neuroendocrine function and inflammation make it a promising target for small molecules and other therapeutic compounds. Further research is needed to fully understand its role and potential as a drug target.

Protein Name: NDRG Family Member 4

Functions: Contributes to the maintenance of intracerebral BDNF levels within the normal range, which is necessary for the preservation of spatial learning and the resistance to neuronal cell death caused by ischemic stress (By similarity). May enhance growth factor-induced ERK1 and ERK2 phosphorylation, including that induced by PDGF and FGF. May attenuate NGF-promoted ELK1 phosphorylation in a microtubule-dependent manner

The "NDRG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDRG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NDST1 | NDST1-AS1 | NDST2 | NDST3 | NDST4 | NDUFA1 | NDUFA10 | NDUFA11 | NDUFA12 | NDUFA13 | NDUFA2 | NDUFA3 | NDUFA3P3 | NDUFA4 | NDUFA4L2 | NDUFA5 | NDUFA5P11 | NDUFA6 | NDUFA6-DT | NDUFA7 | NDUFA8 | NDUFA9 | NDUFAB1 | NDUFAF1 | NDUFAF2 | NDUFAF3 | NDUFAF4 | NDUFAF4P1 | NDUFAF5 | NDUFAF6 | NDUFAF7 | NDUFAF8 | NDUFB1 | NDUFB10 | NDUFB11 | NDUFB2 | NDUFB2-AS1 | NDUFB3 | NDUFB4 | NDUFB5 | NDUFB6 | NDUFB7 | NDUFB8 | NDUFB9 | NDUFC1 | NDUFC2 | NDUFC2-KCTD14 | NDUFS1 | NDUFS2 | NDUFS3 | NDUFS4 | NDUFS5 | NDUFS6 | NDUFS7 | NDUFS8 | NDUFV1 | NDUFV2 | NDUFV2P1 | NDUFV3 | NEAT1 | NEB | NEBL | NECAB1 | NECAB2 | NECAB3 | NECAP1 | NECAP2 | NECTIN1 | NECTIN2 | NECTIN3 | NECTIN3-AS1 | NECTIN4 | NEDD1 | NEDD4 | NEDD4L | NEDD8 | NEDD8-activating enzyme E1 | NEDD8-MDP1 | NEDD9 | NEFH | NEFHP1 | NEFL | NEFM | NEGR1 | NEGR1-IT1 | NEIL1 | NEIL2 | NEIL3 | NEK1 | NEK10 | NEK11 | NEK2 | NEK2-DT | NEK3 | NEK4 | NEK5 | NEK6 | NEK7 | NEK8 | NEK9